These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1811416)

  • 1. Immunochemical characterization of intravenous immunoglobulin preparations.
    Rüfenacht R; Morell
    Allergol Immunopathol (Madr); 1991; 19(5):197-200. PubMed ID: 1811416
    [No Abstract]   [Full Text] [Related]  

  • 2. [Suppression of FcRII by intravenously administerd IgG is dependent of preparation procedures of immunoglobulins].
    Greinacher A; Möckel M; Mueller-Eckhardt C
    Beitr Infusionsther Transfusionsmed; 1994; 32():211-3. PubMed ID: 9480090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the contents of the magic draft IVIg?
    Seite JF; Shoenfeld Y; Youinou P; Hillion S
    Autoimmun Rev; 2008 Jun; 7(6):435-9. PubMed ID: 18558358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of blocking antibodies in Guillain-Barré syndromes: "unblocking" the mystery of action of intravenous immunoglobulin.
    Dalakas MC
    Ann Neurol; 2002 Jun; 51(6):667-9. PubMed ID: 12112069
    [No Abstract]   [Full Text] [Related]  

  • 5. Determination of IgG subclasses of immunoglobulin preparations for intravenous injection and the problems involved.
    Tokano Y; Umezawa Y; Okumura K
    Immunol Res; 1994; 13(1):56-60. PubMed ID: 7897263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
    Buchacher A; Iberer G
    Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of antigen specificities in the monomeric and dimeric fractions of intravenous immunoglobulin.
    Miescher SM; Schaub A; Ghielmetti M; Baumann M; Vogel M; Bolli R; Stadler B
    Ann N Y Acad Sci; 2005 Jun; 1051():582-90. PubMed ID: 16126998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with sandoglobulin.
    Garbett ND; Munro CS; Cole PJ
    Clin Exp Immunol; 1989 Apr; 76(1):8-12. PubMed ID: 2500275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of human immunodeficiency virus from immunoglobulin preparations.
    Lancet; 1986 May; 1(8491):1217-8. PubMed ID: 2422515
    [No Abstract]   [Full Text] [Related]  

  • 10. The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used.
    Djoumerska I; Tchorbanov A; Pashov A; Vassilev T
    Scand J Immunol; 2005 Apr; 61(4):357-63. PubMed ID: 15853919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measles-virus-neutralizing antibodies in intravenous immunoglobulins.
    Audet S; Virata-Theimer ML; Beeler JA; Scott DE; Frazier DJ; Mikolajczyk MG; Eller N; Chen FM; Yu MY
    J Infect Dis; 2006 Sep; 194(6):781-9. PubMed ID: 16941344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
    Buchwald B; Ahangari R; Weishaupt A; Toyka KV
    Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of intravenous immunoglobulin preparations.
    Weisman LE
    Isr J Med Sci; 1994; 30(5-6):459-63. PubMed ID: 8034504
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anti-HLA antibodies (Ab1) and anti-idiotypic antibodies (Ab2) directed against Anti-HLA Ab1 in various preparations of polyspecific immunoglobulins for intravenous use].
    Barocci S; Fenoglio D; Leprini A; Nocera A
    Boll Soc Ital Biol Sper; 1990 Dec; 66(12):1193-200. PubMed ID: 2129237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of experimental autoimmune myasthenia gravis by intravenous immunoglobulin and isolation of a disease-specific IgG fraction.
    Fuchs S; Feferman T; Zhu KY; Meidler R; Margalit R; Wang N; Laub O; Souroujon MC
    Ann N Y Acad Sci; 2007 Sep; 1110():550-8. PubMed ID: 17911471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Technology of immunoglobulin production. I. Technological aspects of purification].
    Volkov GL
    Ukr Biokhim Zh (1999); 2006; 78(3):88-98. PubMed ID: 17100315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Viral safety considerations in immunoglobulin preparations].
    Gómez Manzano P; Escrivá CA; Salmerón García F; Alonso Verduras C
    Sangre (Barc); 1997 Jun; 42(3):199-203. PubMed ID: 9381262
    [No Abstract]   [Full Text] [Related]  

  • 18. Self-reactivity in the dimeric intravenous immunoglobulin fraction.
    Schaub A; Wymann S; Heller M; Ghielmetti M; Beleznay Z; Stadler BM; Bolli R; Miescher S
    Ann N Y Acad Sci; 2007 Sep; 1110():681-93. PubMed ID: 17911483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of target antigens of self-reactive IgG in intravenous immunoglobulin preparations.
    Bussone G; Dib H; Dimitrov JD; Camoin L; Broussard C; Tamas N; Guillevin L; Kaveri SV; Mouthon L
    Proteomics; 2009 Apr; 9(8):2253-62. PubMed ID: 19296548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins.
    St-Amour I; Laroche A; Bazin R; Lemieux R
    Clin Immunol; 2009 Oct; 133(1):52-60. PubMed ID: 19604724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.